Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Do new TB vaccines have a place in the Expanded Program on Immunization?

McMurray DN.

Expert Rev Vaccines. 2011 Dec;10(12):1675-7. doi: 10.1586/erv.11.144.

PMID:
22085170
2.

[Novel vaccines against M. tuberculosis].

Okada M.

Kekkaku. 2006 Dec;81(12):745-51. Review. Japanese.

PMID:
17240920
3.

Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.

Ota MO, Odutola AA, Owiafe PK, Donkor S, Owolabi OA, Brittain NJ, Williams N, Rowland-Jones S, Hill AV, Adegbola RA, McShane H.

Sci Transl Med. 2011 Jun 22;3(88):88ra56. doi: 10.1126/scitranslmed.3002461.

4.

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.

Pathan AA, Sander CR, Fletcher HA, Poulton I, Alder NC, Beveridge NE, Whelan KT, Hill AV, McShane H.

PLoS One. 2007 Oct 24;2(10):e1052. Erratum in: PLoS One. 2011;6(2).doi:10.1371/annotation/71208a01-eb32-469c-96ab-8d5e3c497fce.

5.

MVA-85A, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults.

Nicol MP, Grobler LA.

Curr Opin Mol Ther. 2010 Feb;12(1):124-34. Review.

PMID:
20140824
6.

[BCG vaccines for the prevention of tuberculosis in the world].

Hashimoto T.

Kekkaku. 1997 Nov;72(11):629-37. Japanese.

PMID:
9423301
7.

The hunt for new tuberculosis vaccines: anti-TB immunity and rational design of vaccines.

Xing Z.

Curr Pharm Des. 2001 Jul;7(11):1015-37. Review.

PMID:
11472252
8.

Immunogenicity and protective efficacy of mycobacterial DNA vaccines incorporating plasmid-encoded cytokines against Mycobacterium bovis.

Young SL, Slobbe LJ, Peacey M, Gilbert SC, Buddle BM, de Lisle GW, Buchan GS.

Immunol Cell Biol. 2010 Aug;88(6):651-7. doi: 10.1038/icb.2010.25. Epub 2010 Mar 16.

PMID:
20231853
9.

Enhanced immunogenicity of BCG vaccine by using a viral-based GM-CSF transgene adjuvant formulation.

Wang J, Zganiacz A, Xing Z.

Vaccine. 2002 Jul 26;20(23-24):2887-98.

PMID:
12126899
10.

[Evolution of IGRA researches].

Ariga H, Harada N.

Kekkaku. 2008 Sep;83(9):641-52. Review. Japanese.

PMID:
18979999
11.

[Recent progress in mycobacteriology].

Okada M, Kobayashi K.

Kekkaku. 2007 Oct;82(10):783-99. Japanese.

PMID:
18018602
12.

Feasible improvements in vaccines in the Expanded Programme on Immunization.

McIntosh K.

Rev Infect Dis. 1989 May-Jun;11 Suppl 3:S530-7. Review.

PMID:
2669097
13.

[Frontier of mycobacterium research--host vs. mycobacterium].

Okada M, Shirakawa T.

Kekkaku. 2005 Sep;80(9):613-29. Japanese.

PMID:
16245793
14.

[Strategies for the development of new tuberculosis vaccines].

Fattorini L.

Minerva Med. 2007 Apr;98(2):109-19. Review. Italian.

PMID:
17519853
15.

A novel DNA vaccine containing multiple TB-specific epitopes casted in a natural structure (ECANS) confers protective immunity against pulmonary mycobacterial challenge.

Gao H, Yue Y, Hu L, Xu W, Xiong S.

Vaccine. 2009 Aug 27;27(39):5313-9. doi: 10.1016/j.vaccine.2009.06.093. Epub 2009 Jul 16.

PMID:
19615961
16.
17.

Recent developments in tuberculosis vaccines.

Haile M, Källenius G.

Curr Opin Infect Dis. 2005 Jun;18(3):211-5. Review.

PMID:
15864097
18.

TB vaccines for the World.

Glyn Hewinson R.

Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):1-6. Epub 2005 Jan 17.

PMID:
15687020

Supplemental Content

Support Center